Menu
Back to Journals » OncoTargets and Therapy » Volume 12
RETRACTED ARTICLE: Exosomal Tenascin-c induces proliferation and invasion of pancreatic cancer cells by WNT signaling
Authors Qian S, Tan X , Liu X, Liu P , Wu Y
Received 25 October 2018
Accepted for publication 12 March 2019
Published 29 April 2019 Volume 2019:12 Pages 3197—3205
DOI https://doi.org/10.2147/OTT.S192218
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Takuya Aoki
This paper has been retracted.
Qian S, Tan X, Liu X, Liu P, Wu Y. Onco Targets Ther. 2019;12:3197–3205.
The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised following the authors request to replace invasion and migration images in Figure 4. It appears images in this figure may have been duplicated. Specifically,
- Figure 4A, Invasion, PC-10, appears to have been duplicated with the same image for Figure 4A, Migration, PC-10.
- Figure 4A, Invasion, Aspc-1, appears to have been duplicated with the same image for Figure 4A, Migration, PC-10.
The authors were asked to provide original data that would further verify the reported findings, but they were unable to do this in a satisfactory manner. The Editor requested to retract the article and the authors were notified of this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.